Direxion Daily 20 Year Treasury Bull 3X Shares vs GeneDx Holdings Corp — how do they compare? Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.8 (market cap $2.03B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Direxion Daily 20 Year Treasury Bull 3X Shares and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days and GeneDx Holdings Corp for 19 Days on average.
| TMF | WGS | |
|---|---|---|
Market Cap | $2.03B | $2.02B |
Volume | 12,241,664 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $44.14 | $167.51 |
52-Week Low | $25.19 | $34.51 |
Typical Hold Time | 28 Days | 19 Days |
Enterprise Value | — | $2.05B |
Signals from Pluang's Aura AI — not financial advice
TMF trades at $25.23, down 0.51% with bearish technical signals from moving averages. The ETF saw increased trading volume of 5.2 million shares, indicating heightened investor interest. Key support sits at $24-25 while resistance levels are at $25-26. RSI readings below 20 suggest potential oversold conditions despite the bearish trend.
As a leveraged Treasury ETF, TMF faces interest rate sensitivity and market volatility risks. The bearish technical outlook and Federal Reserve policy uncertainty create headwinds, though oversold conditions may present tactical opportunities for investors anticipating rate cuts.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →